The U.S. vascular access device market will reach over $4.8 billion by 2017, fueled by the adoption of new antimicrobial technologies for central venous catheters (CVCs), dialysis catheters, peripherally inserted central catheters (PICCs) and increased use of power injectable PICCs. Newly released ultrasound and tip-location devices, designed to assist with catheter placement, will also drive growth in the overall vascular access market.
In addition, new catheters incorporating antimicrobial technologies to reduce catheter-based blood stream infections, are gaining increased adoption. Companies such as Teleflex, Cook and C.R. Bard have leveraged antimicrobial technology to develop antimicrobial CVCs, PICCs, and dialysis catheters, which are driving sales in the vascular access market.